Waisi Eng
Seminars
Thursday 23rd July 2026
Investigating the Preclinical Development of [161Tb]Tb-NYM032 for PSMA-targeting Radioligand Therapy
12:00 pm
- Profiling biomarkers to reveal individual treatment responses, helping identify which patients are most likely to benefit from therapy
- Tailoring dosimetry for each patient to optimize efficacy and safety by adjusting doses based on personalized radiation exposure
- Speeding early development through data-driven personalization, using patient-specific information to guide decision-making and trial design
